Action Innoviva - INVA

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

17,92

Prix Achat

17,36

Prix Vente

20,67

Volume échangé

648 545

17,46 Fourchette du Jour 17,99

14,325 Plage de 52 semaines 21,28

Cap du marché

1,122B

Clôture Veille

17,55

Ouverture

17,58

Dernière Transaction

18.19

Dernière heure de transaction

Volume financier

US$ 11 487 044

VWAP

17,712

Volume moyen (3 m)

578 539

Actions en circulation

62 601 081

Rendement du Dividende

Ratio Cours sur Bénéfices

6,24

Bénéfice par action (BPA)

2,87

Chiffre d'affairess

310,46M

Bénéfice net

179,72M

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta an... Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. The firm collaborates with and receives funding from GlaxoSmithKline. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Siège social

Wilmington, Delaware, USA

Fondé

Innoviva Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker INVA. Le dernier cours de clôture d'Innoviva était de US$17,55. Au cours de la dernière année, les actions de Innoviva ont été négociées dans une fourchette de prix de US$ 14,325 à US$ 21,28.

Innoviva compte actuellement 62 601 081 actions en circulation. La capitalisation boursière d'Innoviva est de US$1,10 milliard. Innoviva a un ratio cours/bénéfice (ratio PE) de 6.24.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Core royalty platform continues to deliver with GSK royalties of $66.0 million for the fourth quarter and $255.6 million for the full year...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical...

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva Specialty Therapeutics, Inc., (“IST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive...

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical...

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.26	-1.4301430143	18.18	18.57	17.515	555932	17.8513319	CS
4	-0.79	-4.22234099412	18.71	18.91	17.515	472397	18.11772587	CS
12	-1.08	-5.68421052632	19	19.385	17.01	578539	18.13483981	CS
26	-1.17	-6.1288632792	19.09	21.28	17.01	589868	18.90702457	CS
52	2.54	16.5149544863	15.38	21.28	14.325	588666	17.45879751	CS
156	-1.15	-6.03041426324	19.07	21.28	10.64	696074	15.22375583	CS
260	4.89	37.5287797391	13.03	21.28	7.58	706149	14.61586134	CS

INVA - Frequently Asked Questions (FAQ)

What is the current Innoviva share price?

The current share price of Innoviva is US$ 17,92

How many Innoviva shares are in issue?

Innoviva has 62 601 081 shares in issue

What is the market cap of Innoviva?

The market capitalisation of Innoviva is USD 1,1B

What is the 1 year trading range for Innoviva share price?

Innoviva has traded in the range of US$ 14,325 to US$ 21,28 during the past year

What is the PE ratio of Innoviva?

The price to earnings ratio of Innoviva is 6,24

What is the cash to sales ratio of Innoviva?

The cash to sales ratio of Innoviva is 3,61

What is the reporting currency for Innoviva?

Innoviva reports financial results in USD

What is the latest annual turnover for Innoviva?

The latest annual turnover of Innoviva is USD 310,46M

What is the latest annual profit for Innoviva?

The latest annual profit of Innoviva is USD 179,72M

What is the registered address of Innoviva?

The registered address for Innoviva is CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801

Which industry sector does Innoviva operate in?

Innoviva operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
STAKSTAK Inc	US$ 3,97 (156,13%)	174,23k
ORGOOrganogenesis Holdings Inc	US$ 6,21 (102,28%)	59M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
ARBBARB IOT Group Ltd	US$ 0,6635 (38,23%)	59,08M
NVNINVNI Group Ltd	US$ 0,99 (-50,50%)	72,79M
SPGCSacks Parente Golf Inc	US$ 0,2085 (-48,65%)	58,21M
ADGMAdagio Medical Holdings Inc	US$ 0,8081 (-47,53%)	756,76k
PRAXPraxis Precision Medicines Inc	US$ 38,60 (-40,64%)	3,2M
SAGSAG Holdings Ltd	US$ 1,19 (-38,97%)	789,86k
NVDANVIDIA Corporation	US$ 124,92 (3,97%)	389,48M
TRNRInteractive Strength Inc	US$ 2,57 (67,97%)	193,57M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 13,44 (7,78%)	154,46M
PMAXPowell Max Ltd	US$ 0,511 (43,54%)	137,18M
LCIDLucid Group Inc	US$ 2,22 (-0,45%)	136,17M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Innoviva Inc (INVA) Cours

Innoviva Inc (INVA)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Innoviva Inc

INVA Dernières nouvelles

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Innoviva Reports Fourth Quarter and Full Year 2024 Financial Results; Highlights Recent Company Progress

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Innoviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Innoviva Specialty Therapeutics Signs Exclusive Distribution and Licensing Agreement to Acquire U.S. Marketing Rights for Zevtera® (ceftobiprole)

Innoviva to Participate in the Citi 2024 Global Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Innoviva to Participate in the UBS Global Healthcare Conference

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

INVA - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités